Case studies in clinical research: interview preparation with seven scenarios

These seven hypothetical scenarios are intended for interview preparation. They illustrate issues to discuss with the responsible investigator, sponsor and other relevant specialists. Decisions in an actual study must follow the approved protocol, applicable requirements and the responsibilities of the people involved.

Case 1: unexpected serious adverse effects in a Phase I study

Situation: during an early study of a new medicine, some participants develop serious and unexpected problems, such as organ failure. The original example concerned an oncology medicine; whether healthy volunteers or patients may participate depends on the particular development programme and its risk assessment.

Actions to consider:

1. Protect participants: urgently escalate the findings to the investigator and sponsor. Further dosing or study activity may need to be paused under the protocol and applicable safety procedures; a candidate should not assume authority to close a study independently.

2. Immediate medical care: affected participants need prompt clinical assessment and appropriate treatment by qualified professionals.

3. Safety reporting: notify the responsible study personnel, ethics committee and competent authorities as required, using the applicable reporting categories and timelines.

4. Review the evidence: examine the data, dosing and procedures to investigate possible causes while preserving the original records.

5. Reassess the protocol: review the benefit–risk balance and any necessary protocol or consent changes. Obtain the required approvals before restarting or implementing changes, except where immediate action is needed to remove a hazard.

Case 2: low recruitment in a Phase II study

Situation: a study of a new antidepressant recruits fewer patients than planned, threatening its ability to answer the research question.

Actions to consider:

1. Identify barriers: ask current and potential participants about practical difficulties and reasons for declining, using appropriate and approved methods.

2. Improve communication: review information for patients and families so that the study, its burdens and its uncertainties are understandable.

3. Review eligibility criteria: assess whether any criteria are unnecessarily restrictive. Any change needs a scientific and safety justification and the applicable approvals; recruitment pressure alone is not a reason to weaken safeguards.

4. Address costs fairly: consider appropriate travel reimbursement or practical support. Payment arrangements require ethics review and must not put undue pressure on people to participate.

5. Consider additional sites: assess whether qualified centres in other regions could improve access while maintaining consistent training and oversight.

Case 3: data-management errors in a Phase III study

Situation: important data are lost or recorded incorrectly during collection and management.

Actions to consider:

1. Inspect the system and process: investigate the affected workflows, the extent of the error and its root cause.

2. Check backups and security: determine whether data can be recovered through authorised procedures and whether access controls or backup processes failed.

3. Train the team: give relevant staff targeted training based on the findings rather than treating training as the only corrective measure.

4. Document corrections and prevention: preserve an audit trail, record justified corrections and implement proportionate corrective and preventive actions. Never invent missing observations.

5. Assess the impact: involve data-management and statistical specialists to evaluate the effect on results. Any additional collection must be feasible, justified and consistent with the protocol and required approvals.

Case 4: a serious safety signal in a Phase IV study

Situation: a rare but serious adverse effect is observed in a study of an already marketed medicine for hypertension.

Actions to consider:

1. Report the observation: document the event and escalate it through the appropriate pharmacovigilance channels and regulatory procedures.

2. Assess the risk: evaluate the evidence and the implications of continued use for affected patients and the wider population.

3. Communicate responsibly: the responsible parties should arrange accurate safety information for healthcare professionals and patients, including clinically appropriate alternatives where relevant.

4. Consider regulatory action: restrictions, a recall or withdrawal may be considered by the responsible marketing-authorisation holder and competent authorities. A single observation does not automatically establish the need for market withdrawal.

5. Monitor outcomes: follow affected patients and investigate longer-term consequences through appropriate clinical and safety procedures.

Case 5: an unexpectedly high placebo response in Phase II

Situation: patients receiving placebo improve more than expected, making the treatment comparison harder to interpret.

Actions to consider:

1. Investigate possible explanations: examine the population, natural disease course, outcome measurement, concomitant care and study design.

2. Review participant information: ensure that communication is accurate, consistent and balanced. Do not manipulate expectations or withhold material information to obtain a preferred result.

3. Check blinding and conduct: investigate whether blinding, assessment procedures or site practices could explain the observations, without unnecessarily revealing treatment allocation.

4. Evaluate any design change: additional recruitment or a longer study needs a sound justification and the required protocol and statistical review. It must not simply be used to search for statistical significance.

5. Protect statistical integrity: follow the prespecified analysis plan. Clearly label any additional analyses as exploratory and discuss their limitations; do not present post hoc tests as if they had been planned in advance.

Case 6: poor treatment adherence in Phase III

Situation: many participants do not follow the treatment schedule, for example by taking medicines irregularly. This affects interpretation and may have safety implications.

Actions to consider:

1. Monitor appropriately: consider approved reminders or scheduled calls, respecting privacy and avoiding excessive burden.

2. Talk with participants: explain the schedule and listen to difficulties, including adverse effects, misunderstanding and practical obstacles.

3. Assess protocol burden: consider whether the regimen is unnecessarily complicated. Changes require appropriate scientific, safety and ethics review.

4. Offer suitable support: practical assistance or counselling may help. Any incentives need review and must not pressure participants to remain in the study or conceal problems.

5. Analyse transparently: use the planned methods for adherence and missing data. Separate analyses of adherent participants may have selection bias and should not silently replace the primary analysis.

Case 7: a worsening safety profile after marketing

Situation: previously unrecognised serious adverse effects emerge for a widely used medicine.

Actions to consider:

1. Escalate promptly: report observed events through the appropriate safety system and inform the responsible study and pharmacovigilance personnel.

2. Update risk management: evaluate the signal and identify proportionate measures to reduce risk and gather further evidence.

3. Inform patients and prescribers: coordinate clear, authorised communication about the evidence and any changes to use or monitoring.

4. Review continued supply: where justified, the responsible company and competent authorities may consider restrictions, suspension, recall or withdrawal. These decisions require the relevant evidence and authority.

5. Plan follow-up: assess longer-term outcomes and whether the measures taken are effective, documenting findings and lessons for future studies.

Across all seven scenarios, a strong interview response explains who is responsible, how participants will be protected, what evidence is needed and how actions will be documented. Prompt, ethical and scientifically sound responses support reliable research; no checklist can guarantee a study’s success.